IMPEDIMED LIMITED — Capital/Financing Update 2017

Oct 23, 2017

==> picture [226 x 43] intentionally omitted <==

24[th] October 2017

ASX ANNOUNCEMENT

ImpediMed Quarterly Results and Investor Conference Call

Brisbane, Australia - ImpediMed Limited (ASX: IPD) advises it will release its Appendix 4C Cash Flow Statement and Quarterly Results for the period ending September 30, 2017 on Wednesday October 25.

Investors are invited to join a conference call with Managing Director and CEO, Richard Carreon at 9.15am – 10.15am AEST on Wednesday October 25, 2017.

To pre-register please follow this link: https://services.choruscall.com.au/diamondpass/impedimed-493650-invite.html

You will receive a calendar notification with dial in details and a PIN for fast track access to the call.

For further information please contact:

Richard Carreon, ImpediMed Managing Director & CEO Morten Vigeland, ImpediMed CFO T: +1 (760) 585-2100

Media and Investor Contacts:

In Australia:

Kyahn Williamson, WE Buchan T: +61 3 9866 4722 E: kwilliamson@we-buchan.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., and a European office in Thessaloniki, Greece, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed was the first company to receive FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men, for its L-Dex[®] device. In addition, ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO™, sold in select markets globally.

For more information, visit www.impedimed.com.